Brain Imaging and Neuroimaging Market Snapshot
“The Brain Imaging and Neuroimaging Market to grow from USD 12.89 billion in 2023 to USD 18.72 Billion by 2030, at a CAGR of 5.67%.”
What does brain imaging signify?
The study of brain structure and function is conducted using non-invasive computer methods like positron emission tomography, computed tomography, and magnetic resonance imaging.
What's the term for neuroimaging?
Neuroimaging is a non-invasive method used to study the human brain's anatomy and function using quantitative tools, and is increasingly being used in quantitative research on mental health and brain disorders.
Brain imaging technology allows noninvasive mapping of brain structure and functioning through three methods: measuring brain activity currents and magnetic fields, injecting radioactive agents to identify specific regions, or measuring tissue reactions to external energy sources.
These signals provide unique insights into brain anatomical features and physiological functions, answering questions about structural integrity in clinical settings and connecting brain activity to human cognition and behavior.
Neuroimaging is a diverse field involving computer technology, psychology, statistics, and neuroscience, aiming to identify brain lesions caused by inflammatory diseases, tumors, strokes, and vascular disease.
Radiologists, medical professionals specializing in neuroradiology, use non-statistical brain imaging in therapeutic settings. Neuroradiology is qualitative, based on subjective impressions and clinical experience, while neuroimaging uses quantitative techniques.
fMRI and other functional brain imaging techniques are commonly used in neuroimaging but less frequently in neuroradiology, with two main groups.
- Structural imaging is a method used to measure brain structure, such as voxel-based morphometry.
- Functional imaging, including fMRI and other techniques like PET and MEG, is a method used to study brain function.
>>>Download Sample Report Now:https://marketreportservice.com/request-sample/brain-imaging-and-neuroimaging-market-54713
Brain-imaging techniques
Computed axial tomography- Computed tomography (CT) and Computed Axial Tomography (CAT) scanning are medical procedures that use multiple head x-rays from different angles to evaluate brain damage.
CT scans use computer software to calculate the amount of x-ray beam absorbed in a small brain volume, often displayed as brain cross-sections.
Magnetic resonance imaging- Magnetic resonance imaging (MRI) uses magnetic fields and radio waves to create high-quality images of brain regions, with the Massachusetts General Hospital's postmortem intact brain showing the finest spatial resolution of 100 microns.
Positron emission tomography- Postron emission tomography (PET) and brain positron emission tomography measure emissions from metabolically active substances injected into the bloodstream, providing two- or three-dimensional representations of chemical distribution across the brain through computer processing.
PET scanning is a powerful method that uses substances to visualize blood flow, oxygen and glucose metabolism, and functional brain regions. It provides insight into brain functioning by indicating activity levels in different areas. Initially, PET scans outperformed other metabolic imaging techniques in resolution and completion time.
Single-photon emission computed tomography- Single-photon emission computed tomography (SPECT) is a method that uses gamma ray-emitting radioisotopes and a gamma camera to create two- or three-dimensional images of active brain areas.
The SPECT agent, injected subcutaneously, is quickly absorbed by the brain, indicating cerebral blood flow (CBF) at the time of injection. This makes SPECT ideal for imaging epilepsy patients, which can be challenging due to mobility issues and varying seizure patterns.
Segment Analysis
Segmented by Imaging Type
Functional Magnetic Resonance Imaging
Functional magnetic resonance imaging (fMRI) is a technique that detects blood flow variations in brain activity, aiding in identifying brain areas responsible for vital functions, assessing stroke impact, and facilitating direct brain therapy, outperforming other imaging methods in identifying brain abnormalities.
Magnetic resonance imaging (MRI) is a noninvasive test used by doctors to diagnose medical disorders. It creates detailed images of internal body structures using radiofrequency pulses, a strong magnetic field, and a computer.
MRI helps doctors evaluate patients and identify diseases. Functional magnetic resonance imaging (fMRI) measures blood flow variations in a specific brain area.
Compound Tomography
A CT scan is a diagnostic imaging technique that uses computer technology and X-rays to create detailed images of the inside of the body, including bones, muscles, fat, organs, and blood arteries.
Compared to regular X-rays, CT scans provide more detail by directing an energy beam at the body part under examination and capturing its fluctuations through tissues like skin, muscle, and bone.
Standard X-rays provide a lot of information but lack detail about inside organs or other structures.
positron emission tomography
PET scans are a nuclear medicine technique that monitors the metabolic activity of body tissues' cells, combining nuclear medicine with biochemical analysis.
Typically used in patients with cancer, heart disease, or brain disorders, PET helps visualize biochemical changes, such as heart muscle metabolism, which converts food into energy after digestion.
Growth Drivers
The market growth in neurological disorders is driven by the rise in mortality rates, the need for neuroimaging technologies, and ongoing brain mapping research. Governments are also promoting public understanding of neurological disorders and the available therapies, as they aim to reduce the burden on healthcare systems.
Furthermore, the field is growing as additional neurologic diseases are discovered by the application of methods from optogenetics, magnetic resonance imaging (MRI), microscopy, and electrophysiology.
In order to expand their product offerings and obtain a competitive advantage, the top corporations are also creating innovative medical devices that have higher efficacy and patient compliance.
Restraints
The field of neurology is expanding as more neurologic diseases are discovered using optogenetics, MRI, microscopy, and electrophysiology. Top corporations are developing innovative medical devices with higher efficacy and patient compliance to gain a competitive advantage.
Neuroimaging technologies, such as MRI and PET scanners, require significant research and development costs, often included in service charges. The cost of these devices is influenced by initial investment and maintenance expenses.
The cost of neuroimaging may vary based on the healthcare system in a country or region, with public healthcare often covered by insurance, and private healthcare systems with patients bearing more of the cost. The interpretation and analysis of neuroimaging data also require specialized knowledge, potentially increasing service costs.
Opportunities
PET imaging is crucial for assessing brain cellular functions, such as glucose metabolism and neurotransmitter activity, and diagnosing and tracking neurodegenerative diseases like Alzheimer's and Parkinson's.
As PET technology's capabilities improve, new radiotracers and hybrid imaging systems are being developed to increase its availability for clinical use. This market opportunity is expected due to the advancements in various imaging approaches.
Trends
The global market for brain imaging and neuroimaging is expected to grow due to the increasing number of neurogenerative diseases and the rise in accidents and injuries.
Alzheimer's disease affects 5 to 7 million Americans 65 and older, with dementia affecting 4.7 million. This growth is attributed to brain abnormalities associated with the disease.
Competitive Landscape of the Brain Imaging and Neuroimaging Market Analysis
New Developments in Brain Imaging and Neuroimaging Market
Oct 10, 2023- Philips and World Stroke Organization partner to improve access to high-quality stroke care
Royal Philips a global leader in health technology, and the World Stroke Organization (WSO), the world’s only global non-governmental organization focused on stroke, announced the signing of a two-year partnership aimed at improving access to high-quality stroke care.
Building on their shared commitment to delivering improvements in stroke prevention, treatment, rehabilitation and support, Philips and WSO will leverage their respective strengths to elevate the public understanding of stroke as a global health issue, starting with joint initiatives on World Stroke Day 2023 (October 29) to build greater public awareness, which is fundamental to improving stroke patient outcomes. They will also work together to support the implementation of innovative treatment methods with the potential to transform the stroke care pathway, where reducing the time between symptom onset and effective treatment is critical to improving patient outcomes.
November 16, 2022- Sick and Tired: A New Study Is Using GE’s Experimental MRI to Examine How Poor Sleep Affects the Brain
It’s practically endemic in the modern world. The college student finishing a term paper as the sun comes up, the new parents feeding the baby at 3 a.m., the foreman on the graveyard shift — they’re all among the more than a third of adults in the U.S. who don’t get enough sleep. Long-term, sleep deprivation can have severe ramifications, beyond what can be remedied by a double espresso or a power nap. In fact, recent research indicates that regularly getting less than seven hours of sleep per night can raise your risk of developing dementia later in life by nearly a third.
In August 2022, Siemens Smart Infrastructure (SI), the market leader in digital buildings, completed the acquisition of Brightly Software, a leading asset and maintenance management software-as-a-service (SaaS) provider based in the United States. The acquisition propels SI to the forefront of the software market for buildings and built infrastructure. It combines Brightly's well-established cloud-based capabilities in key sectors such as education, public infrastructure, healthcare, and manufacturing with Siemens' digital and software expertise in buildings.
In August 2022, Ernst & Young LLP and GE Digital announced a partnership to assist organizations in transforming their manufacturing operations. The alliance combines EY USA's proven sector expertise and technology consulting services with GE's over 100 years of manufacturing experience and rich digital technology.
March 4, 2021- Hitachi Launches New Open MRI Systems at ECR 2021
Hitachi Medical Systems launched two new permanent open MRI systems at the start of the 2021 European Congress of Radiology. Both systems are equipped with SynergyDrive workflow solution.
Regional Analysis of Global Brain Imaging and Neuroimaging Industry
North America holds the largest market share in brain imaging technology, with modern facilities accessible due to the region's strong healthcare infrastructure. This facilitates efficient data collection and utilization by researchers and medical practitioners.
Numerous North American countries support and encourage these fields through subsidies, grants, and financial incentives. Collaboration between industry, academia, and healthcare providers in North America leads to the development of new technology, software, and methods for brain imaging, ensuring findings are applied in clinical settings.
Western Europe is expected to experience significant growth in brain imaging and neuroimaging due to funding from public and commercial sectors, significant investments in neuroscience development, and collaborations between academic institutions and businesses. The market for brain imaging benefits from healthy competition and teamwork, encouraging growth and creativity. The increasing prevalence of neurological disorders like Parkinson's, Alzheimer's, and multiple sclerosis in Western Europe necessitates advanced brain imaging technologies for early detection, accurate diagnosis, and ongoing monitoring.
Segments Covered in the Brain Imaging and Neuroimaging Market Report
Brain Imaging and Neuroimaging Market Segment by Imaging Type
- Functional Magnetic Resonance Imaging (FMRI)
- Compound Tomography (CT)
- Positron Emission Tomography (PET)
- Electroencephalography (EEG)
- Magnetoencephalography (MEG)
- Near Infrared Spectroscopy (NIRS)
Brain Imaging and Neuroimaging Market Segment By End User
- Electric Current
- Iontophoresis
- Electroporation
- Ultrasound
- Microporation
Brain Imaging and Neuroimaging Market by Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
- Latin America
Frequently Asked Questions
What are some applications of Brain Imaging and Neuroimaging?
Neuroradiology is a medical specialty that uses non-statistical brain imaging to identify brain lesions like vascular disease, strokes, tumors, and inflammatory diseases, practiced by radiologists.
What is the expected growth rate of the Brain Imaging and Neuroimaging market over the next 7 years?
The Brain Imaging and Neuroimaging Market to grow from USD 12.89 billion in 2023 to USD 18.72 Billion by 2030, at a CAGR of 5.67%.
Who are the major players in the Brain Imaging and Neuroimaging market and what is their market share?
Varian Medical Systems, General Electric Company, Siemens AG, Philips Healthcare, Toshiba Medical Systems, Hitachi Medical Systems, Esaote SpA, Sanrad Medical Systems Pvt. Ltd, are prominent players operating and dominating in the market.
Who are the top 3 Brain Imaging and Neuroimaging Market Key Vendors?
Varian Medical Systems, General Electric Company, Siemens AG, are key players in the Brain Imaging and Neuroimaging market.
Which geographical areas dominate the worldwide market for Brain Imaging and Neuroimaging?
North America region are emerging as the top regional markets for Brain Imaging and Neuroimaging solutions.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Brain Imaging and Neuroimaging Market
5.1. COVID-19 Landscape: Brain Imaging and Neuroimaging Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Brain Imaging and Neuroimaging Market, By Imaging Type
8.1. Brain Imaging and Neuroimaging Market, by Imaging Type, 2023-2030
8.1.1. Functional Magnetic Resonance Imaging (fMRI)
8.1.1.1. Market Revenue and Forecast (2023-2030)
8.1.2. Computed Tomography (CT)
8.1.2.1. Market Revenue and Forecast (2023-2030)
8.1.3. Positron Emission Tomography (PET)
8.1.3.1. Market Revenue and Forecast (2023-2030)
8.1.4. Electroencephalography (EEG)
8.1.4.1. Market Revenue and Forecast (2023-2030)
8.1.5. Magnetoencephalography (MEG)
8.1.5.1. Market Revenue and Forecast (2023-2030)
8.1.6. Near infrared Spectroscopy (NIRS)
8.1.6.1. Market Revenue and Forecast (2023-2030)
Chapter 9. Global Brain Imaging and Neuroimaging Market, By End User
9.1. Brain Imaging and Neuroimaging Market, by End User, 2023-2030
9.1.1. Hospitals
9.1.1.1. Market Revenue and Forecast (2023-2030)
9.1.2. Ambulatory Surgical Centers
9.1.2.1. Market Revenue and Forecast (2023-2030)
9.1.3. Clinics and Diagnostic Centers
9.1.3.1. Market Revenue and Forecast (2023-2030)
Chapter 10. Global Brain Imaging and Neuroimaging Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Imaging Type (2023-2030)
10.1.2. Market Revenue and Forecast, by End User (2023-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Imaging Type (2023-2030)
10.1.3.2. Market Revenue and Forecast, by End User (2023-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Imaging Type (2023-2030)
10.1.4.2. Market Revenue and Forecast, by End User (2023-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Imaging Type (2023-2030)
10.2.2. Market Revenue and Forecast, by End User (2023-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Imaging Type (2023-2030)
10.2.3.2. Market Revenue and Forecast, by End User (2023-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Imaging Type (2023-2030)
10.2.4.2. Market Revenue and Forecast, by End User (2023-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Imaging Type (2023-2030)
10.2.5.2. Market Revenue and Forecast, by End User (2023-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Imaging Type (2023-2030)
10.2.6.2. Market Revenue and Forecast, by End User (2023-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Imaging Type (2023-2030)
10.3.2. Market Revenue and Forecast, by End User (2023-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Imaging Type (2023-2030)
10.3.3.2. Market Revenue and Forecast, by End User (2023-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Imaging Type (2023-2030)
10.3.4.2. Market Revenue and Forecast, by End User (2023-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Imaging Type (2023-2030)
10.3.5.2. Market Revenue and Forecast, by End User (2023-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Imaging Type (2023-2030)
10.3.6.2. Market Revenue and Forecast, by End User (2023-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Imaging Type (2023-2030)
10.4.2. Market Revenue and Forecast, by End User (2023-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Imaging Type (2023-2030)
10.4.3.2. Market Revenue and Forecast, by End User (2023-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Imaging Type (2023-2030)
10.4.4.2. Market Revenue and Forecast, by End User (2023-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Imaging Type (2023-2030)
10.4.5.2. Market Revenue and Forecast, by End User (2023-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Imaging Type (2023-2030)
10.4.6.2. Market Revenue and Forecast, by End User (2023-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Imaging Type (2023-2030)
10.5.2. Market Revenue and Forecast, by End User (2023-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Imaging Type (2023-2030)
10.5.3.2. Market Revenue and Forecast, by End User (2023-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Imaging Type (2023-2030)
10.5.4.2. Market Revenue and Forecast, by End User (2023-2030)
Chapter 11. Company Profiles
11.1. GE
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Siemens
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Canon
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Hitachi Medical Systems
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Medtronic PLC.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. EB Neuro S.p.A.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Neurosoft
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. MinFound Medical Systems Co. Ltd.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Elekta
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Varian medical Systems
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
![Brain Imaging and Neuroimaging Market Growth Analysis Research Report segmented by Imaging Type [Functional Magnetic Resonance Imaging (FMRI), Compound Tomography (CT), Positron Emission Tomography (PET), Electroencephalography (EEG), Magnetoencephalography (MEG) and Near Infrared Spectroscopy (NIRS)], By End User (Hospitals, Ambulatory Surgical Centers and Clinics and Diagnostic Centers), and Regional Forecast till 2030](storage/categories_images/05b44a1c850434abc748b1c660b9d49d.jpeg "Brain Imaging and Neuroimaging Market Growth Analysis Research Report segmented by Imaging Type [Functional Magnetic Resonance Imaging (FMRI), Compound Tomography (CT), Positron Emission Tomography (PET), Electroencephalography (EEG), Magnetoencephalography (MEG) and Near Infrared Spectroscopy (NIRS)], By End User (Hospitals, Ambulatory Surgical Centers and Clinics and Diagnostic Centers), and Regional Forecast till 2030")